Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.39 |
| ▸ | CASP3 | P42574 | 4/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22284883 | 0.93 | MDM4 (0.42) | MDM4TP53PTPN1CASP3MDM2 | |
| SCHEMBL17531773 | 0.93 | MDM4 (0.42) | MDM4TP53PTPN1CASP3MDM2 | |
| SCHEMBL31643427 | 0.89 | MDM4 (0.48) | MDM4TP53CASP3MDM2 | |
| SCHEMBL29528478 | 0.88 | KMT2A (0.38) | MDM4TP53PTPN1 | |
| SCHEMBL31720358 | 0.88 | MDM4 (0.47) | MDM4TP53PTPN1CASP3MDM2 | |
| SCHEMBL17531777 | 0.86 | MEN1 (0.44) | — | |
| SCHEMBL30302162 | 0.86 | PTPN1 (0.44) | PTPN1CASP3 | |
| SCHEMBL19375786 | 0.85 | MDM4 (0.43) | MDM4TP53PTPN1CASP3MDM2 | |
| SCHEMBL30954823 | 0.85 | EPHX2 (0.46) | MDM4TP53PTPN1CASP3 | |
| SCHEMBL12683457 | 0.85 | EPHX2 (0.46) | MDM4TP53PTPN1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367307-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | TORAY INDUSTRIES, INC. (JP) | 2025-12-04 | — | — | US | disclosed |
| US-20250281630-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | TORAY INDUSTRIES, INC. (JP) | 2025-09-11 | — | — | US | disclosed |
| US-20250249092-A1 | CONJUGATE OF CAPRIN-1 ANTIBODY LINKED TO IMMUNE ACTIVATOR FOR CANCER TREATMENT | TORAY INDUSTRIES, INC. (JP) | 2025-08-07 | — | — | US | disclosed |
| EP-4548932-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER | Toray Industries, Inc. (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-12274745-B2 | Conjugate of CAPRIN-1 antibody linked to immune activator for cancer treatment | TORAY INDUSTRIES, INC. (JP) | 2025-04-15 | — | — | US | disclosed |
| WO-2025058000-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING AND/OR DIAGNOSING CANCER | 東レ株式会社 | 2025-03-20 | — | — | WO | disclosed |
| EP-4400121-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER | Toray Industries, Inc. (JP) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023033129-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER | 東レ株式会社 | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367307-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | CAPRIN1, NOS1, NCBP1 | MDM4 2219/4885TP53 116/4885PTPN1 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.